Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

Recent & Breaking News (TSXV:TLT)

Theralase Increases Revenue 22% for 2017 Financial Statements

Filing Services Canada April 30, 2018

Theralase Provides Update on Phase Ib Non-Muscle Invasive Bladder Cancer (NMIBC) Clinical Study

Filing Services Canada April 16, 2018

Theralase Discovers Cannabinoid Increases Efficacy of Patented Anti-Cancer Technology in Destruction of Brain Cancer

Filing Services Canada March 27, 2018

Theralase Anti-Cancer Technology Effective in Destroying Brain Cancer Stem Cells

Filing Services Canada March 15, 2018

Rutherrin(R) Technology Granted Allowance for Canadian Patent

Filing Services Canada March 7, 2018

Theralase Advances Anti-Cancer Technology in Destruction of Human Lung Cancer

Filing Services Canada March 5, 2018

Theralase Announces Settlement Agreement with Ontario Securities Commission

Filing Services Canada February 26, 2018

Theralase Anti-Cancer Technology Treats Sixth Patient for Bladder Cancer

Filing Services Canada February 9, 2018

Correcting and Replacing: Theralase Anti-Cancer Technology Used to Treat Fifth Patient for Bladder Cancer

Filing Services Canada January 18, 2018

Theralase Anti-Cancer Technology Used to Treat Fifth Patient for Bladder Cancer

Filing Services Canada January 18, 2018

Theralase Optimizes Delivery Schedule of Anti-Cancer Vaccine in Destruction of Brain Cancer

Filing Services Canada January 17, 2018

Theralase Discovers Theralase(R) Cold Laser Therapy Enhances Cancer Destruction for Standard Cancer Treatments

Filing Services Canada November 30, 2017

Theralase Increases Revenue 12% for 3Q2017 Financial Statements

Filing Services Canada November 29, 2017

Theralase Therapeutic Laser Technology Enhances Cancer Destruction

Filing Services Canada November 27, 2017

Theralase Anti-Cancer Vaccine Validated in Colorectal Cancer

Filing Services Canada November 22, 2017

Theralase Demonstrates 24 Months Stability of Second Clinical Batch of Lead Anti-Cancer Drug

Filing Services Canada November 21, 2017

Theralase Discovers New Anti-Cancer Vaccine

Filing Services Canada November 20, 2017

IIROC Trading Resumption - TLT

Canada NewsWire November 13, 2017

IIROC Trading Halt - TLT

Canada NewsWire November 13, 2017

IIROC Trade Halt - Theralase Technologies Inc.

Newsfile November 13, 2017